Palvella Therapeutics (PVLA) Cash from Financing Activities (2016 - 2024)
Historic Cash from Financing Activities for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to $74.8 million.
- Palvella Therapeutics' Cash from Financing Activities rose 60595.36% to $74.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $87.1 million, marking a year-over-year increase of 164178.0%. This contributed to the annual value of $87.1 million for FY2024, which is 164178.0% up from last year.
- Latest data reveals that Palvella Therapeutics reported Cash from Financing Activities of $74.8 million as of Q4 2024, which was up 60595.36% from $2.4 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Cash from Financing Activities registered a high of $74.8 million during Q4 2024, and its lowest value of -$14.8 million during Q4 2023.
- Moreover, its 5-year median value for Cash from Financing Activities was $5.7 million (2021), whereas its average is $10.5 million.
- Data for Palvella Therapeutics' Cash from Financing Activities shows a peak YoY increase of 693950.18% (in 2023) and a maximum YoY decrease of 1599354.84% (in 2023) over the last 5 years.
- Over the past 5 years, Palvella Therapeutics' Cash from Financing Activities (Quarter) stood at $75000.0 in 2020, then skyrocketed by 6434.67% to $4.9 million in 2021, then crashed by 98.1% to $93000.0 in 2022, then plummeted by 15993.55% to -$14.8 million in 2023, then skyrocketed by 605.95% to $74.8 million in 2024.
- Its Cash from Financing Activities was $74.8 million in Q4 2024, compared to $2.4 million in Q3 2024 and $9.9 million in Q2 2024.